Last reviewed · How we verify
BMN 111
BMN 111 is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) to promote bone growth and increase height.
BMN 111 is a C-type natriuretic peptide (CNP) analog that activates natriuretic peptide receptor B (NPR-B) to promote bone growth and increase height. Used for Achondroplasia (to increase adult height), Other skeletal dysplasias (under investigation).
At a glance
| Generic name | BMN 111 |
|---|---|
| Also known as | Modified recombinant human C-type natriuretic peptide, Vosoritide, Modified C-Natriuretic Peptide, ProCNP38 |
| Sponsor | BioMarin Pharmaceutical |
| Drug class | CNP analog |
| Target | Natriuretic peptide receptor B (NPR-B) |
| Modality | Small molecule |
| Therapeutic area | Rare genetic disorders / Endocrinology |
| Phase | Phase 3 |
Mechanism of action
BMN 111 mimics the action of C-type natriuretic peptide, a naturally occurring hormone that signals through NPR-B receptors in the growth plate cartilage. By activating this pathway, the drug stimulates endochondral ossification and longitudinal bone growth, thereby increasing adult height. This mechanism addresses the underlying pathophysiology of skeletal dysplasias characterized by impaired bone growth.
Approved indications
- Achondroplasia (to increase adult height)
- Other skeletal dysplasias (under investigation)
Common side effects
- Injection site reactions
- Headache
- Nausea
- Hypotension
Key clinical trials
- Vosoritide for Selected Genetic Causes of Short Stature (PHASE2)
- A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia (PHASE2)
- An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia (PHASE3)
- An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia (PHASE2)
- A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH) (PHASE2)
- A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia (PHASE2)
- Bioequivalence Study to Compare Two Injection Devices for BMN 111 in Healthy Participants (PHASE1)
- A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BMN 111 CI brief — competitive landscape report
- BMN 111 updates RSS · CI watch RSS
- BioMarin Pharmaceutical portfolio CI